Dupixent Special Drug Use Investigation for long term use (Prurigo nodularis)

Not Applicable

• Conditions: Prurigo nodularis

• Registration Number: JPRN-UMIN000051970
• Lead Sponsor: Sanofi K.K.

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2023-08-25
• Last Update Posted: 17 October 2023
• Study Completion: 2025-06-30

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

Not provided

Exclusion Criteria

Subjects who are participating in or have been registered for clinical trials with therapeutic intervention to Dupixent

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Safety:Incidence rates of adverse drug reactions, Safety specification items of Dupixent Effectiveness:Investigator's Global Assessment for PN-Stage(IGA PN-S), Investigator's Global Assessment for PN-Activity(IGA PN-A), Worst-itch numeric rating scale(WI-NRS)